Important clinical pharmacologic considerations in the use of methadone in cancer patients

D. S. Ettinger, P. J. Vitale, D. L. Trump

Research output: Contribution to journalArticlepeer-review

Abstract

The manufacturer's recommended dose of methadone which is 2.5-10 mg ever 3-4 hours, is excessive. Methadone has an average primary-phase half-life of 14.3 hours and a slower secondary-phase half-life averaging 54.8 hours. Administering the recommended dose of methadone and escalating doses within 2-3 days may lead to very high plasma levels of the drug. In addition, factors such as drug-drug interaction and/or hepatic and renal dysfunction may affect the metabolism of methadone and result in its accumulation. Methadone is an effective analgesic whose pharmacokinetics must be appreciated in order for it to be used safely and effectively. Three cases of methadone overdose are presented.

Original languageEnglish (US)
Pages (from-to)457-459
Number of pages3
JournalCancer Treatment Reports
Volume63
Issue number3
StatePublished - Dec 1 1979

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Important clinical pharmacologic considerations in the use of methadone in cancer patients'. Together they form a unique fingerprint.

Cite this